Perhaps production costs, had a component of capex repayment lingering at start of q.. ?
"Net operating cash inflows for the quarter were $15.3 million, there was no material capital expenditure and
all development capital provided by Pilbara Resources Group was repaid with the Alliance now moving into
full profit sharing at 70% GWR and 30% PRG under the terms of the Alliance contract.
• Unaudited C1 FOB cash costs for the quarter were A$120.3 per wmt and the realised sales price was A$278
per dmt, or A$241 per dmt FOB
• Shipping costs increased slightly through the quarter with a competitive market for Panamax size vessels,
the maximum size able to be loaded from the Port of Geraldton. These costs varied from US$22 per wmt to
US$28 per wmt through the quarter"
Does sales price $A278 , come or $A241 FOB inclusive of shipping ?
If so Please correct my math then. - $A241 FOB - $A120.3 = $A120 margin ? x 220,764 x 70% = 18.5m profit margin to us.
Then you have the administration costs, etc.other write offs.
- Forums
- ASX - By Stock
- GWR
- Ann: June Quarter Activities Report and Appendix 5B
Ann: June Quarter Activities Report and Appendix 5B, page-15
-
- There are more pages in this discussion • 54 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add GWR (ASX) to my watchlist
(20min delay)
|
|||||
Last
8.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $27.62M |
Open | High | Low | Value | Volume |
8.5¢ | 8.6¢ | 8.5¢ | $25.15K | 293.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 18178 | 8.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.6¢ | 98397 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 18178 | 0.084 |
2 | 122102 | 0.083 |
1 | 12195 | 0.082 |
1 | 190000 | 0.081 |
3 | 372500 | 0.080 |
Price($) | Vol. | No. |
---|---|---|
0.086 | 98397 | 1 |
0.088 | 50006 | 1 |
0.090 | 50431 | 1 |
0.092 | 123633 | 2 |
0.096 | 11794 | 1 |
Last trade - 11.57am 13/11/2024 (20 minute delay) ? |
Featured News
GWR (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online